Trial reportPsychopharmacology2006
Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone.
Trial report in Psychopharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 86 citations in OpenAlex.
- Effect of medroxyprogesterone on depressive symptoms in depressed and nondepressed perimenopausal and postmenopausal women after discontinuation of transdermal estradiol therapy.Menopause (New York, N.Y.) · 2012Trial
- Studies of pharmacokinetic and pharmacodynamic properties of isoallopregnanolone in healthy women.Psychopharmacology · 2009Trial
- Facial emotion recognition and amygdala activation are associated with menstrual cycle phase.Psychoneuroendocrinology · 2008Trial
- How progesterone impairs memory for biologically salient stimuli in healthy young women.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007Trial
- Ovarian hormones, hormonal contraceptives and reward processing.BJPsych advances · 2026Article
- Effects of the Menstrual Cycle Phase on Cortisol Responses to Maximum Exercise in Women With and Without Premenstrual Syndrome.Endocrines · 2025Article
- Diagnostic and therapeutic use of oral micronized progesterone in endocrinology.Reviews in endocrine & metabolic disorders · 2024Review
- Allopregnanolone and mood in the peripartum: a longitudinal assessment in healthy women.Frontiers in behavioral neuroscience · 2024Article
- Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA.Neuroscience and biobehavioral reviews · 2023Review
- Allopregnanolone Is Associated with a Stress-Induced Reduction of Heart Rate Variability in Premenstrual Dysphoric Disorder.Journal of clinical medicine · 2023Article
- Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids.International journal of molecular sciences · 2022Review
- Neurosteroids (allopregnanolone) and alcohol use disorder: From mechanisms to potential pharmacotherapy.Pharmacology & therapeutics · 2022Review
- Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome.Faculty reviews · 2022Review
- Neuroactive steroids and depression in early pregnancy.Psychoneuroendocrinology · 2021Article
- Menstrual Cycle, Psychological Responses, and Adherence to Physical Exercise: Viewpoint of a Possible Barrier.Frontiers in psychology · 2021Article
- Progesterone, reproduction, and psychiatric illness.Best practice & research. Clinical obstetrics & gynaecology · 2020Review
- Lowered Plasma Steady-State Levels of Progesterone Combined With Declining Progesterone Levels During the Luteal Phase Predict Peri-Menstrual Syndrome and Its Major Subdomains.Frontiers in psychology · 2019Article
- Neurosteroid Actions in Memory and Neurologic/Neuropsychiatric Disorders.Frontiers in endocrinology · 2019Review
- Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study.Psychopharmacology · 2016Article
- GABAA Receptor-Modulating Steroids in Relation to Women's Behavioral Health.Current psychiatry reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleAllopregnanolone effects on mood in postmenopausal women are unclear thus far.
objectivesAllopregnanolone is a neuroactive steroid with contradictory effects. Anaesthetic, sedative, and anxiolytic as well as aggressive and anxiogenic properties have been reported. The aim of this study is to compare severity of negative mood between women receiving different serum allopregnanolone concentrations during progesterone treatment. MATERIALS AND
methodsA randomized, placebo-controlled, double-blind, crossover study of postmenopausal women (n=43) treated with 2 mg estradiol daily during four treatment cycles. Oral micronized progesterone at 30, 60, and 200 mg/day, and placebo were added sequentially to each cycle. Participants kept daily symptom ratings using a validated rating scale. Blood samples for progesterone and allopregnanolone analyses were collected during each treatment cycle.
resultsDuring progesterone treatment, women had significantly higher negative mood scores when allopregnanolone serum concentration was in the range of 1.5-2 nmol/l compared to lower and higher concentrations. In addition, women displayed a significant increase in negative mood during the progesterone treatment period, compared to the estradiol-only period when 30 mg progesterone daily was used. On the other hand, treatment with higher doses of progesterone had no influence on negative mood.
conclusionsMood effects during progesterone treatment seem to be related to allopregnanolone concentration, and a bimodal association between allopregnanolone and adverse mood is evident.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.